Source-grounded facts extracted from Edwards Lifesciences Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Theodora Mistras was appointed as Corporate Vice President, Chief Financial Officer at Edwards Lifesciences Corp.
“On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.”
Edwards Lifesciences Corp updated its first quarter of 2026 guidance (raised).
“issued a press release setting forth Edwards' financial results for the first quarter of 2026.”
David T. Feinberg was appointed as Director at Edwards Lifesciences Corp.
“On July 10, 2024, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), appointed David T. Feinberg, M.D. to the Company’s Board of Directors (the “Board”), effective immediately.”
Andrew M. Dahl was appointed as Principal Accounting Officer at Edwards Lifesciences Corp.
“On the Retirement Date, Mr. Sellers will be succeeded by Andrew M. Dahl, currently Senior Vice President and Corporate Controller of the Company.”
Robert W.A. Sellers departed as Senior Vice President, Principal Accounting Officer at Edwards Lifesciences Corp.
“Robert W.A. Sellers, Senior Vice President, Principal Accounting Officer of the Company, of his decision to retire, effective as of July 1, 2024”
Edwards Lifesciences Corp shareholders approved The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program at the 2024-05-07 meeting.
“Proposal 4 : The approval of the Company’s Amended and Restated Long-Term Stock Incentive Compensation Program was approved as set forth below:”
Edwards Lifesciences Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-07 meeting.
“Proposal 3 : Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved as set forth below:”
Edwards Lifesciences Corp shareholders approved Advisory proposal regarding the Company’s named executive officer compensation at the 2024-05-07 meeting.
“Proposal 2 : The advisory proposal regarding the Company’s named executive officer compensation was approved as set forth below:”
Edwards Lifesciences Corp shareholders approved Election of Directors at the 2024-05-07 meeting.
“All the nominees for director listed in Proposal 1 were elected to serve until the Company’s next annual meeting of stockholders and until their respective successors are duly elected and qualified as set forth below:”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.